Shares of Hoth Therapeutics, Inc. (HOTH) are rising more than 100% Thursday morning after the company said the FDA accepted Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.
EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.
The company plans to start its Phase 2a study of HT-001 in the first quarter of 2023.
HOTH is at $9.59 currently. It has traded in the range of $2.61-$43.75 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.